Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Preventing heart attack and stroke in patients with kidney disease

Preventing heart attack and stroke in patients with kidney disease

Stories Sep 4, 2022 3 minutes

Researchers found that almost 40 per cent of eligible patients 50 years and older were not receiving a protective heart medication.

Statins can prevent heart conditions among patients with chronic kidney disease who have not started dialysis or received a kidney transplant. Yet, new research from Vancouver Coastal Health Research Institute researcher Dr. Hilary Wu indicated that these patients were often not receiving this potentially life-saving medication.

Wu’s study, published in the Canadian Journal of Hospital Pharmacy, highlights the need for new oversight and protocols when it comes to prescribing statins to older adult patients with chronic kidney disease. 

“While we know the benefits of statins for chronic kidney disease patients who have had a previous heart attack or stroke, statin use can also help prevent these serious conditions among older patients who have not had any cardiovascular events.” 

Chronic kidney disease happens when there is a loss of kidney function, which, in severe cases, can lead to kidney failure and death. Diminished kidney function allows wastes, excess fluids and electrolytes to build up in the body. Chronic kidney disease patients often have atherosclerotic disease, where cholesterol causes plaque deposits that narrow artery walls, increasing the risk of heart attacks and strokes. 

Change is needed for statin prescription rates to rise

Statins are a prescribed medication class that lowers cholesterol levels in the blood and reduces the risk of heart disease and stroke. Interest in this medication class rose after the 2011 SHARP clinical trial, which linked statins to a reduction in cardiovascular events among patients with chronic kidney disease. 

Canadian Cardiovascular Society guidelines now recommend statins for patients with chronic kidney disease aged 50 and older who are not treated with a kidney transplant or dialysis.

Dr. Hilary Wu is a clinical pharmacy specialist in nephrology with the Kidney Care Clinic at Vancouver General Hospital.

Wu’s study found that, of the 813 patients aged 50 and older who attended the Vancouver General Hospital Kidney Care Clinic (KCC) for treatment and were eligible for statins, only 63 per cent were taking the medication. In addition, seven out of the nine KCC nephrologists surveyed in the study stated that they never or rarely prescribed statins to KCC patients before a cardiovascular condition is diagnosed.  

“Many nephrologists said that they felt statin prescription fell more into the scope of family physicians.”

Several factors contributed to surveyed nephrologists’ reluctance to prescribe the cholesterol-reducing medication, says Wu. Given the limited frequency of KCC visits, they felt that prescribing and monitoring medication adherence and potential adverse events would be better performed by patients’ family physicians.

Nephrologists also listed concerns about potential drug interactions and the additional pill burden that statins could pose.  

However, Wu’s study found an openness among nephrologists to implement strategies to support greater statin use among KCC patients. Strategies they endorsed included “educating family physicians; creating preprinted orders and laboratory requisitions for statin initiation; providing educational materials about statins to patients; and implementing a protocol for KCC pharmacists to counsel patients about statins.”

“Our study shows that we need a more detailed discussion with nephrologists about the risk factors they look for when determining if someone is a good candidate for statin use, and we need to promote statin prescribing among patients who could benefit from it.”

“We also need to provide education to family physicians, potentially in the form of a letter that notifies them if the nephrologist recommends statin use and at what dosage,” says Wu.

Moving forward, Wu plans to develop these materials to support the care of older chronic kidney disease patients receiving treatment through the KCC, and to continue to monitor statin prescribing rates. She thanks Mazen Sharaf, Dr. Karen Shalansky and Dr. Nadia Zalunardo for their support and expertise in conducting this study. 
 

Researchers

Hilary Wu
Nadia Zalunardo
Karen Shalansky

Related Articles

Ask an expert: What should I know about kidney stones?

Transforming kidney transplantation with pioneering epitope-based matching

Blood type matters for kidney patient priority

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Other Research Focus Areas

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy